Upgrade to SI Premium - Free Trial

Biogen (BIIB)

230.63 +4.89 (2.17%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/23/24)
- M&A (12/31/23 *Est)

Latest Headlines

Scotiabank Reiterates Sector Outperform Rating on Biogen (BIIB) June 12, 2024 10:10 AM - StreetInsider Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises June 11, 2024 8:45 AM - StreetInsider Eli Lilly inches higher premarket after FDA advisory panel backs Alzheimer's drug June 11, 2024 8:33 AM - StreetInsider BIOGEN NOTICE: If You Suffered Losses on Your Biogen Inc. (Nasdaq: BIIB) Investment, You are Reminded to Contact BFA Law Before Approaching July 2024 Legal Deadline June 11, 2024 6:43 AM - StreetInsider BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. June 10, 2024 12:44 PM - StreetInsider Eisai, Biogen (BIIB) announced FDA acceptance of sBLA for LEQEMBI IV maintenance dosing June 9, 2024 10:13 PM - StreetInsider FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease June 9, 2024 6:37 PM - Globe NewsWire FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease June 9, 2024 6:30 PM - PR NewsWire BIOGEN CASE DEADLINE: Biogen Inc. (Nasdaq: BIIB) Investors are Reminded of Upcoming July 2024 Legal Deadline and Encouraged to Contact BFA Law June 8, 2024 5:11 AM - StreetInsider BIIB Class Action Reminder: Contact Robbins LLP for Information About Your Rights Against Biogen Inc. June 7, 2024 5:13 PM - StreetInsider RBC Capital Reiterates Outperform Rating on Biogen (BIIB) June 7, 2024 9:14 AM - StreetInsider Stifel Reiterates Buy Rating on Biogen (BIIB) June 6, 2024 10:10 AM - StreetInsider RBC Capital Reiterates Outperform Rating on Biogen (BIIB) June 6, 2024 9:50 AM - StreetInsider Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm June 5, 2024 9:00 PM - StreetInsider UPCOMING DEADLINE ALERT: Biogen Inc. (Nasdaq: BIIB) Investors are Encouraged to Contact BFA Law About Approaching July 2024 Deadline in Securities Class Action June 5, 2024 3:26 PM - StreetInsider RBC Capital Reiterates Outperform Rating on Biogen (BIIB) June 5, 2024 6:11 AM - StreetInsider BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. June 4, 2024 1:45 AM - StreetInsider BIOGEN 50 DAY NOTICE: Investors of Biogen Inc. (Nasdaq: BIIB) are Encouraged to Contact BFA Law Before July 2024 Deadline in Securities Fraud Class Action June 3, 2024 4:04 PM - StreetInsider Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel June 3, 2024 7:30 AM - StreetInsider BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit June 2, 2024 9:52 AM - StreetInsider BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm June 1, 2024 9:00 PM - StreetInsider BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline June 1, 2024 5:33 AM - StreetInsider BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action May 31, 2024 9:00 PM - StreetInsider Biogen (BIIB) Receives European Commission Approval for QALSODY, the First Therapy to Treat a Rare, Genetic Form of ALS May 30, 2024 4:52 PM - StreetInsider Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS May 30, 2024 4:51 PM - Globe NewsWire BIOGEN ALERT: BFA Law Announces Biogen Inc. (Nasdaq: BIIB) Sued for Securities Fraud after Significant Stock Drops - Contact the Firm if You Suffered Losses May 29, 2024 3:16 PM - StreetInsider Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion May 29, 2024 7:03 AM - StreetInsider RBC Capital Reiterates Outperform Rating on Biogen (BIIB) May 29, 2024 5:31 AM - StreetInsider BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm May 28, 2024 9:00 PM - StreetInsider BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline May 28, 2024 2:30 PM - StreetInsider "LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea May 28, 2024 4:32 AM - StreetInsider BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit May 25, 2024 8:36 AM - StreetInsider BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm May 24, 2024 9:00 PM - StreetInsider Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB) May 24, 2024 8:19 PM - StreetInsider BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. May 24, 2024 12:30 PM - StreetInsider BMO Capital Reiterates Outperform Rating on Biogen (BIIB) May 23, 2024 7:34 AM - StreetInsider BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead the Biogen Class Action Lawsuit May 22, 2024 7:50 PM - StreetInsider Stifel Reiterates Buy Rating on Biogen (BIIB) Following Acquisition of HI-Bio May 22, 2024 9:41 AM - StreetInsider Piper Sandler Reiterates Overweight Rating on Biogen (BIIB) Following Acquisition of HI-Bio May 22, 2024 9:33 AM - StreetInsider Morgan Stanley on Biogen (BIIB) Acquisition of Hi-Bio May 22, 2024 9:25 AM - StreetInsider Biogen in up to $1.8 billion deal as rare diseases take center stage May 22, 2024 7:37 AM - StreetInsider Biogen (BIIB) to Acquire Human Immunology Biosciences for $1.15B Upfront Plus Milestone Payments May 22, 2024 7:31 AM - StreetInsider Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences May 22, 2024 7:30 AM - StreetInsider Biogen (BIIB) and Ionis (IONS) Report Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis May 16, 2024 7:31 AM - StreetInsider Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis May 16, 2024 7:30 AM - PR NewsWire Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis May 16, 2024 7:30 AM - Globe NewsWire Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track May 14, 2024 7:33 PM - Globe NewsWire Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track S May 14, 2024 7:30 PM - PR NewsWire Form 4 BIOGEN INC. For: May 01 Filed by: Keeney Adam May 3, 2024 8:01 PM - SEC Filing Biogen Reports Progress on Corporate Responsibility Priorities May 2, 2024 7:30 AM - Globe NewsWire Form ARS BIOGEN INC. For: Dec 31 April 26, 2024 5:17 PM - SEC Filing Form DEFA14A BIOGEN INC. April 26, 2024 5:05 PM - SEC Filing Form DEF 14A BIOGEN INC. For: Jun 20 April 26, 2024 5:03 PM - SEC Filing Biogen (BIIB) Receives Positive CHMP Opinion for TOFIDENCE April 25, 2024 4:41 PM - StreetInsider Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® April 25, 2024 4:05 PM - StreetInsider Biogen (BIIB) PT Lowered to $331 at Morgan Stanley April 25, 2024 8:53 AM - StreetInsider Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright April 25, 2024 7:23 AM - StreetInsider Biogen (BIIB) PT Raised to $308 at Canaccord Genuity April 25, 2024 6:57 AM - StreetInsider Biogen (BIIB) PT Lowered to $317 at RBC Capital April 25, 2024 6:39 AM - StreetInsider Biogen (BIIB) PT Lowered to $340 at Goldman Sachs April 25, 2024 6:21 AM - StreetInsider Biogen (BIIB) PT Lowered to $340 at Goldman Sachs April 25, 2024 6:20 AM - StreetInsider Biogen (BIIB) PT Lowered to $200 at Barclays April 25, 2024 3:31 AM - StreetInsider Form 10-Q BIOGEN INC. For: Mar 31 April 24, 2024 4:16 PM - SEC Filing Biogen (BIIB) PT Raised to $215 at Wedbush April 24, 2024 4:06 PM - StreetInsider JPMorgan First Take on Biogen (BIIB) April 24, 2024 9:06 AM - StreetInsider BMO Capital First Take on Biogen (BIIB) Earnings April 24, 2024 7:57 AM - StreetInsider Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall April 24, 2024 7:43 AM - StreetInsider Form 8-K BIOGEN INC. For: Apr 24 April 24, 2024 7:03 AM - SEC Filing Biogen (BIIB) tops earnings expectations but revenue falls short April 24, 2024 7:02 AM - StreetInsider Biogen cost cuts drive profit beat, as Alzheimer's drug off to slow start April 24, 2024 6:48 AM - StreetInsider Biogen (BIIB) Tops Q1 EPS by 24c; reaffirms guidance April 24, 2024 6:46 AM - StreetInsider Biogen (BIIB) April weekly option implied volatility into quarter results April 23, 2024 11:07 AM - StreetInsider Biogen (BIIB) PT Lowered to $270 at Oppenheimer April 19, 2024 7:22 AM - StreetInsider Biogen (BIIB) PT Lowered to $214 at UBS April 17, 2024 8:14 AM - StreetInsider Form PRE 14A BIOGEN INC. For: Jun 20 April 12, 2024 5:02 PM - SEC Filing Biogen (BIIB) PT Lowered to $260 at BofA Securities April 12, 2024 9:21 AM - StreetInsider Biogen (BIIB) PT Lowered to $339 at Morgan Stanley April 9, 2024 9:40 AM - StreetInsider Biogen (BIIB) PT Lowered to $215 at Barclays April 4, 2024 4:17 AM - StreetInsider Form 4 BIOGEN INC. For: Apr 02 Filed by: Singhal Priya April 3, 2024 8:25 PM - SEC Filing Form 4 BIOGEN INC. For: Apr 01 Filed by: Murphy Nicole April 3, 2024 8:12 PM - SEC Filing Form 144 BIOGEN INC. Filed by: Singhal Priya April 2, 2024 10:08 AM - SEC Filing Biogen's (BIIB) Leqembi filing setback 'negative for sentiment' April 1, 2024 6:40 AM - StreetInsider Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA March 31, 2024 7:30 PM - PR NewsWire Full Article List